Daihan Pharmaceutical Co.,Ltd. (KOSDAQ:023910)

Daihan Pharmaceutical Cash Flow Statement

Financials in millions KRW. Fiscal year is January - December.

Operating Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	27,528	27,644	33,759	28,426	24,961	22,670
Depreciation & Amortization	11,633	9,221	7,282	8,663	9,208	11,411
Loss (Gain) From Sale of Assets	-18.36	-31.38	-58.03	-22.53	9.4	-41.28
Loss (Gain) From Sale of Investments	137.44	-274.01	-303.6	-288.69	-	-
Provision & Write-off of Bad Debts	-42	24.34	17.05	10.8	-33.29	-142.8
Other Operating Activities	4,757	2,406	2,115	4,194	2,632	7,386
Change in Accounts Receivable	-1,595	199.83	-385.22	437.93	-2,172	-10.94
Change in Inventory	-3,573	-8,134	-3,194	1,271	-4,407	2,969
Change in Accounts Payable	955.53	1.13	526.47	-877.61	2,997	-389.71
Change in Other Net Operating Assets	-2,449	-5,452	-4,115	-2,954	-4,194	-3,234
Operating Cash Flow	37,333	25,604	35,643	38,860	28,999	40,617
Operating Cash Flow Growth	8.49%	-28.16%	-8.28%	34.00%	-28.60%	20.79%

Investing Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Capital Expenditures	-17,168	-25,123	-15,801	-21,280	-8,621	-11,850
Sale of Property, Plant & Equipment	18.36	31.4	58.04	22.53	-	41.66
Investment in Securities	-4,687	-12,521	-56,883	3,235	8,635	283.86
Other Investing Activities	-	0	0	25	180	10
Investing Cash Flow	-21,837	-37,612	-72,626	-17,998	193.48	-11,515

Financing Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Short-Term Debt Repaid	-	-	-	-2,500	-200	-1,000
Long-Term Debt Repaid	-	-37.12	-38.79	-4,080	-16,817	-4,300
Total Debt Repaid	-48	-37.12	-38.79	-6,580	-17,017	-5,300
Net Debt Issued (Repaid)	-48	-37.12	-38.79	-6,580	-17,017	-5,300
Repurchase of Common Stock	-	-	-	-	-3,418	-
Dividends Paid	-5,772	-5,195	-4,329	-3,752	-2,108	-2,108
Financing Cash Flow	-5,820	-5,232	-4,368	-10,332	-22,543	-7,408

Net Cash Flow

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Foreign Exchange Rate Adjustments	824.77	-89.82	1,152	113.04	441.94	671.96
Miscellaneous Cash Flow Adjustments	-	-	-	-	0	-0
Net Cash Flow	10,501	-17,329	-40,199	10,644	7,092	22,367

Free Cash Flow

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Free Cash Flow	20,165	481.53	19,841	17,580	20,378	28,767
Free Cash Flow Growth	46.37%	-97.57%	12.86%	-13.73%	-29.16%	1.77%
Free Cash Flow Margin	9.31%	0.23%	9.72%	8.97%	11.06%	16.78%
Free Cash Flow Per Share	-	81.89	3374.38	2989.79	3405.01	4794.57
Levered Free Cash Flow	12,284	-4,364	12,013	13,570	17,249	25,715
Unlevered Free Cash Flow	12,285	-4,363	12,014	13,603	17,620	26,009

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash Interest Paid	2.03	2.69	1.81	52.47	582.23	451.55
Cash Income Tax Paid	6,006	7,913	8,028	8,656	8,869	3,247
Change in Working Capital	-6,662	-13,385	-7,168	-2,123	-7,777	-665.87

Data Source: S&P Global Market Intelligence Last updated: Jul 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 10, 2026

Data Sources Report a data error